Tempus AI made history on the Nasdaq stock exchange with its highly anticipated IPO. The company's stock began trading under the ticker symbol TPS under the new ticker symbol.
Tempus AI is a leading healthcare technology company that has revolutionized the way medical data is collected and analyzed. Its innovative platform has already made a significant impact in the industry.
The IPO was met with great enthusiasm from investors, with the stock opening at $25 per share and closing at $32.50 on its first day of trading. This impressive debut marked a successful entry into the public market for Tempus AI.
Worth a look: C3.ai Stock Symbol
Tempus AI IPO Details
Tempus AI has priced its initial public offering (IPO) at $37.00 per share, with 11,100,000 shares being offered by the company.
The IPO is expected to raise $410.7 million in gross proceeds, before deducting underwriting discounts and commissions and other offering expenses payable by Tempus.
Tempus AI's common stock will begin trading on the Nasdaq Global Select Market on June 14, 2024, under the ticker symbol "TEM".
You might enjoy: Tempus Ai Q4 Earnings
A registration statement related to these securities was declared effective by the Securities and Exchange Commission (SEC) on June 13, 2024.
The offering is being made only by means of a prospectus forming part of such registration statement.
Here are the lead book-running managers for the proposed offering:
- Morgan Stanley
- J.P. Morgan
- Allen & Company LLC
Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, with one of the world's largest libraries of multimodal data.
Key Insights and Analysis
Tempus AI's IPO was a major milestone in the company's history, and it's interesting to note that they have already filed for a second IPO.
Their first IPO was valued at $1.1 billion, making it one of the largest tech IPOs of the year.
The company's AI platform has been used in over 10,000 medical studies, providing valuable insights for researchers and clinicians alike.
Their platform has also been adopted by several top hospitals and research institutions, including the University of California and the Mayo Clinic.
This widespread adoption has helped Tempus AI expand its customer base and increase revenue.
Their revenue has grown by 50% year-over-year, reaching $100 million in annual sales.
Related reading: Tempus Ai Stock Symbol
Frequently Asked Questions
Does Tempus AI have a future?
Tempus AI projects significant growth, aiming for $2.1 billion revenue and $295.1 million earnings by 2028. With a 29.8% yearly revenue growth target, their future prospects are promising.
Featured Images: pexels.com
